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ABSTRACT 
Objective: The objective of the study was to evaluate and optimize compression process variables of Esomeprazole (Multiunit 
particulate system) MUPS tablet. 
Materials and methods: A three-factor, two-level, full factorial design was used to investigate the influence process variables Viz. 
Main compression force, Pre-compression force and Turret speed. Responses studied were Weight variation, Hardness, Thickness, 
Friability, Content uniformity, Drug release in 0.1N HCl at 120min and drug release in pH 6.5 simulated intestinal fluid at 15 min. 
Results and discussion: Main compression force and the Pre-compression force had a significant influence on hardness, thickness, 
drug release in 0.1N HCl at 120min and drug release in pH 6.5 SIF at 15min. Higher compression force leads to breakage of pellets 
during compression which showed impact drug release at acid stage. Turret speed had significant impact on final weight variation 
and content uniformity. The optimized process parameters Main compression force: 11.33 kP, Pre-compression force: 2.72 Kp and 
Turret speed: 23.56 rpm showed desired physical characteristics and drug release in 0.1N HCl which will result in lesser degradation 
of API at acid stage. 
Conclusion: It is concluded that Compression process variables in preparation of Esomeprazole MUPS were successfully evaluated 
using Design of Experiment approach. 
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INTRODUCTION  
Solid oral controlled and modified release drug delivery 
systems are the most acceptable and reliable dosage 
form to patients.  Multi-particulate systems (MUPS) are 
mainly oral dosage forms consisting of a multiplicity of 
small discrete units, each exhibiting some desired 
characteristics. In these systems, the dosage of the drug 
substances is divided on a plurality of subunit, typically 
consisting of thousands of spherical particles
1
. MUPS 
offer various advantages over other systems, including 
reduced risk of local irritation and toxicity, predictable 
bioavailability, reduced likelihood of dose dumping, 
minimized fluctuations in plasma concentration of drug, 
and high dose-strength administration
2
. 
Compression of pellets is a major challenge which 
involves segregation of pellets in hopper as well as on 
turret. Turret speed may lead to segregation of pellets 
which may have impact on final DP-CQA’s Assay, drug 
release and content uniformity of tablets
3,4
. Other factors 
that may have impact on DP-CQAs are size, shape and 
density of pellets, nature of polymer and polymer 
coating, amount of polymer coating and nature and 
amount of extra-granular excipients
5-8.
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Esomeprazole Magnesium selected as model drug for 
study, which belongs to Proton pump inhibitors class. 
Proton pump inhibitors are potent inhibitors of acid 
secretion. These compounds are susceptible to 
degradation in acid media. Therefore, formulation was 
prepared using enteric coating polymers and finally 
compressed into MUPS tablet to avoid degradation of 
drug in acidic pH and irritation to gastric mucosa. 
Experimental design and statistical modelling are 
essential tools for the development and understanding of 
complicated formulations and processes. Design of 
experiment (DoE) approach can be used to understand 
impact of formulation factors/process variables. Further 
it allows efficient experimentation covering a large 
number of factors which are varied together over a set of 
experiments, in contrast with the traditional approach of 
varying each factor while keeping other factors constant, 
which may fail to identify any interactions between 
these factors
9, 10, 11
. In current study, a computer-aided 
optimization technique using a three factor, two-level, 
full factorial design was used to investigate the effect of 
three process variables, i.e., Main compression force, 
Pre-compression force, and Turret speed. 
MATERIALS & METHODS  
Materials  
Esomeprazole Magnesium was obtained as a gift sample 
from Hetero Drugs. Ludipress LCE and Crospovidone 
(Kollidon CL-F) was gifted from BASF. Prosolv SMCC 
HD 90, Prosolv SMCC 90 and Sodium stearyl fumarate 
were obtained from JRS Pharma. PEG 6000 was 
obtained from Sigma Aldrich. All the chemicals and 
reagents were of analytical reagent (AR) grade and used 
without further purifications. 
Methods 
Preparation of lubricated blend 
All extra granular excipients were sifted through 30 
mesh (Table 1). Esomeprazole Magnesium over coated 
pellets with Prosolv SMCC HD 90 were co-sifted 
through 30 mesh, labelled as co-sift I. Crospovidone, 
PEG 6000 and 1/2th quantity of ludipress LCE were 
sifted through30 mesh and labelled as co-sift II. Aerosil 
with remaining quantity of ludipress LCE were sifted 
through 30 mesh, labelled as co-sift III. Initial pre-sifted 
Prosolv SMCC 90 added to double cone blender 
followed by co-sift I, co-sift II, co-sift III and mixed for 
10 min with 10rpm. 
Table 1: Composition details for Esomeprazole 
Magnesium MUPS tablets 
Sr. 
No. 
Ingredients 
Mg/tab 
1 Top coated pellets 263.28 
2 Ludipress LCE 280.96 
3 Prosolv SMCC HD 90 135.00 
4 Prosolv SMCC  90 135.00 
5 PEG 6000 70.00 
6 Crospovidone 20.00 
7 Sodium stearyl fumarate 6.00 
8 Colloidal silicon dioxide (Aerosil 200) 4.00 
 Total 914.24 
 
Compression 
Tablets were compressed using Protab 21station 
compression machine having unit weight 914.24mg 
(Tooling Details: 19.3*9.7mm, oval shaped). 
Compression parameters evaluated ranges shown in 
table 2. 
Experimental design  
A number of preliminary experiments were conducted to 
determine the critical process variables by which the 
process resulted in quality of MUPS. Design Expert 
software was used in our study for generation and 
evaluation of the statistical experimental design. A 
three-factor, two-level, full factorial design was 
employed for the optimization procedure. The main 
compression force (X1, kN), Pre-compression force (X2, 
kN), and Turret speed (X3, rpm) were selected as the 
independent variables, whereas Weight variation (Y1), 
Hardness (Y2), Thickness (Y3), Content uniformity (Y4), 
Drug release in 0.1N HCl at 2hrs (Y5), and drug release 
in pH 6.5 simulated intestinal fluid at 15 min (Y6) were 
chosen as the dependent variables. Table 2 summarizes 
these process variables with corresponding levels and 
the responses studied, whereas experimental runs with 
different process variables are listed in Table 3. The 
variables were selected to measure the change in 
response from one extreme factor to another and for 
determining interactions, if any, among the factors with 
their best levels for optimizing the considered 
experimental responses. 
 
Table 2: Three Factor, two level Full Factorial Experimental Design: Factors selected and responses measured 
Factors (Process variables) 
Levels of factors used in 
process optimization studies 
Responses to be studied 
-1 1 
Y1: Weight variation - % RSD 
Y2:  Hardness,  
Y3: Thickness  
Y4: Content uniformity 
Y5 Drug release in 0.1N HCl at 2hrs 
Y6: Drug release in pH 6.5 simulated 
intestinal fluid at 15 min. 
Main compression force  
(X1, kN) 
9 13 
Pre-compression force 
 (X2,kN), 
2 4 
Turret speed (X3, rpm) 15 45 
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Table 3: Esomeprazole Magnesium MUPS tablet compression variables as per 2
3 
Full Factorial Experimental 
Design 
Run 
Process Variable X1 
(Main compression force,kN) 
Process Variable X2 
(Pre-compression force, kN) 
Process Variable X3 
(Turret speed, rpm) 
RUN 1 13 2 45 
RUN 2 9 2 45 
RUN 3 13 2 15 
RUN 4 9 4 45 
RUN 5 9 4 15 
RUN 6 13 4 45 
RUN 7 13 4 15 
RUN 8 9 2 15 
 
Physicochemical Characterization of Esomeprazole 
MUPS tablet 
Dissolution studies 
Dissolution studies were carried out in two stages. 
Dissolution in acidic condition i.e., 0.1N HCl for 2 hrs 
with volume 500 mL, USP apparatus II (Paddle)and 
temperature 37±0.5
o
C followed by dissolution in pH 
6.5,simulated intestinal condition for 45 min with 
volume 500 mL, USP apparatus II (Paddle) and 
temperature 37±0.5
o
C. 
Content uniformity – AV value 
Content uniformity was evaluated by USP method (905) 
and acceptance value (AV) calculated at different turret 
speed and compression force. 
Weight variation - % RSD 
Weighed individually 20 tablets selected at random and 
calculated the average weight. Study repeated three 
times for each formulation (n=3). Weighing balance 
used Mettler Toledo. 
Hardness 
Tablet hardness was measured from the force required to 
fracture tablets by diametrical compression using a 
tablet hardness Tester (Erweka TBH200, Germany). 
Mean hardness of 10 tablets from each formulation was 
observed and reported as tablet hardness (n=10).  
Friability 
Friability of tablets was determined using Friabilator 
(Electrolab, India). Ten tablets were added in a 
friabilator at 25 rpm and dropping. The percent friability 
was then calculated by, 
       Percent Friability = (W-Wo/W) x 100 
Where, Wo is the weight of the tablets before the test 
and W is the weight of the tablet after the test. 
Statistical Analysis 
Design Expert software was used for generation of 
polynomial models, including interaction terms for all 
response variables using multiple linear regression 
analysis. Polynomial models together with interaction 
terms were generated for all the response variables by 
means of multiple linear regression analysis. The 
influence of various process variables and their 
interaction with each of the responses are represented 
graphically. In order to validate the polynomial 
equations, one optimum checkpoint and three random 
checkpoints were selected by intensive grid search, 
performed over the entire experimental domain. Values 
were predicted for each process variable using a 
mathematical model developed for the optimized 
process and three additional random checkpoints 
covering the entire range of the experimental domain. 
These predicted values were compared with the 
resulting experimental values and the percentage bias 
was calculated. 
RESULTS AND DISCUSSION 
Risk Assessment and Justification  
A risk assessment of the Compression process was 
performed to identify the high-risk unit operations that 
could affect the final DP-CQAs. The process variables 
that could impact the identified drug product CQAs 
were the focus of risk assessment to determine which 
variables have the highest potential to cause CQA 
failures. These variables were then investigated in order 
to optimize compression process variables and mitigate 
the risk of failure. 
The initial risk assessment of the compression process is 
shown in the table 4 below. Tooling design and size was 
fixed at initial stages of development trials hence risk 
considered ass Low. During preliminary trials. feeder 
speed was evaluated in range 15-30rpm and proposed 
during optimization studies. Hence initial risk 
considered as low. Pre-compression force and Main 
compression force may have impact on intermedia CQA 
hardness and thickness, which may have impact on 
dissolution of tablets. Higher compression force may 
lead to breakage of pellets which may lead to drug 
release in Acid medium. Hence risk considered as High 
for DP-CQA Dissolution. High turret speed may lead to 
weight variation of tablets which may have impact on 
DP-CQA content uniformity and assay of tablets. Hence 
risk considered as High. Lubricant quantity may have 
impact on ejection force. Lubricant used sodium stearyl 
fumarate was optimized during formulation evaluation 
and ejection force found 200-300. Hence risk considered 
as low. Environmental conditions were monitored 
during process. Hence risk considered as low. 
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Table 4: Initial Risk Assessment for Compression Process Variables 
CQA's 
Compression Process steps 
Tooling 
design 
Feeder speed 
Pre-compression 
force 
Main 
compression 
force 
Turret 
speed 
Ejection 
force 
Environmental 
conditions 
Intermediate CQA's 
Weight 
Variation 
Low Low 
Low Low High Low Low 
Hardness Low Low High High Low Low Low 
Thickness Low Low Medium Medium Low Low Low 
Finished product CQA's 
Assay  Low Low Low Low Low Low Low 
Dissolution Low Low High High Medium Low Low 
content 
uniformity 
-AV value 
Low Low Low Low High Low Low 
Water 
content 
Low Low Low Low Low Low Low 
Related 
Substances 
Low Low Low Low Low Low Low 
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Compression: 
During compression process with each run MUPS tablets were evaluated for 
intermediate CQAs Weight, thickness, hardness, disintegration, friability and DP-
CQAs as Content uniformity, assay and drug release. The core tablets of different 
batches as per design showed friability values less than 0.2%, hence Friability was 
not included as response during evaluation. Details for eight experimental design 
batches and responses observed shown in table 5. 
 
Table 5: Result data of mean values of various responses for all the 8 batches of experimental design 
Run Process Variables Y1: Weight 
variation 
(% RSD) 
 
Y2: 
Hardness 
(kp) 
Y3: 
Thickness 
(mm) 
Y4: Content 
Uniformity - 
AV value 
Y5: Drug 
release in 
0.1N HCl 
at 2hrs 
 
Y6: Drug 
release in pH 
6.5 simulated 
intestinal fluid 
at 15 min. 
Main 
compression 
force, kN 
Pre-compression 
force, kN 
Turret speed, 
rpm 
RUN 1 13 2 45 3.42 18.4 6.89 5.57 6 68 
RUN 2 9 2 45 3.14 11.3 7.2 6.42 2 72 
RUN 3 13 2 15 2.16 18.2 6.86 3.13 7 63 
RUN 4 9 4 45 2.83 11.3 7.18 6.77 3 76 
RUN 5 9 4 15 1.67 12.6 7.16 1.87 4 67 
RUN 6 13 4 45 3.59 19.6 6.82 7.91 11 64 
RUN 7 13 4 15 1.93 19.3 6.8 2.98 9 61 
RUN 8 9 2 15 1.23 11 7.22 2.51 3 74 
RUN 9 13 2 45 3.42 18.4 6.89 5.57 6 68 
 
Factorial design  
Experiments were carried out to determine the mathematical relationship between 
the process variables acting on the system and the response of the system. The 
statistical evaluation of experimental outcomes was processed with Design Expert 
software to find the optimum levels. 
A first order polynomial regression equation that fitted the data is as follows:  
Y = b0 + b1 X1 + b2 X2 + b3 X3 + b12X1 X2 + b13X1 X3 + b23X2 X3 + b123X1 X2 X3 
(1) 
Here b0 is the arithmetic mean of all the quantitative outcomes of the eight 
experimental runs; b1 –b3 are the estimated coefficients from the observed 
experimental values of Y for X1, X2, and X3. The interactions terms Xi XjXk (i, j, 
and k = 1, 2, and 3) shows how the change in response occurs when two or more 
factors are simultaneously changed. The equation represents the quantitative effect 
of factors upon the each of the responses. A positive sign in front of the terms 
indicates a synergistic effect while a negative sign indicates an antagonistic effect 
of the factors. The significance of the model was estimated by applying analysis 
of variance (ANOVA) at the 5% significance level. A model was considered 
significant if the P value was less than 0.05. 
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 Evaluation of Effect of Process Parameters on 
selected Responses and ANOVA analysis 
Note: In equation process variables Main compression 
force, Pre-compression force and turret speed to indicate 
as A, B & C respectively. 
1. Weight Variation- (% RSD) 
Weight variation in tablets occurs due improper flow of 
blend & High turret speed. Weight variation was 
evaluated during all runs as per experimental design. 
Weight Variation (RSD) 
=+2.50+0.2787*A+0.7488*C+0.1437*ABC 
(F=302.33, P˂0.0001, R2=0.995) 
From equation it is observed that Main compression 
force and turret speed have positive effect on weight 
variation. Maximum effect observed in case of process 
variable Turret speed. 
Same can be observed from Pareto chart (Fig. 1a), where 
main compression force and turret speed show effect 
more than Bonferroni limit showing almost certainly 
significant. 
2. Hardness and Thickness 
Main compression force and pre-compression force may 
have impact on Hardness of tablets which will have 
impact on drug product CQA. 
Hardness = +15.21+3.66*A+0.4875*B 
(F=268.67, P˂0.0001, R2=0.990) 
Thickness = +7.02-0.1738*A-0.0263*B 
(F=453.26, P˂0.0001, R2=0.994) 
From equation it is observed that Main compression 
force and Pre-compression force have positive effect on 
hardness of tablet. Maximum effect observed in case of 
process variable Main compression force, same can be 
observed from Pareto chart (Fig.1b and 1c). For 
response thickness, main compression force showed 
negative effect i.e. increases in level of main 
compression force leads to decrease in thickness. 
3. Content Uniformity – AV value 
Unoptimized turret speed may have impact on content 
uniformity of final tablets, which will have impact on 
Assay of final tablets.  
Content Uniformity – AV value= +4.65+ 2.02*C 
(F=302.33, P˂0.0001, R2=0.994) 
From equation it is observed that turret speed has 
positive effect on content uniformity of tablets i.e. 
increase in turret speed leads to higher weight variation 
which finally impact on content uniformity of tablets. 
Same can be observed from Pareto chart (Fig.1d), where 
turret speed show effect more than Bonferroni limit 
showing almost certainly significant. 
5. Drug release in 0.1N HCl at 120 min and drug 
release in pH 6.5 SIF at 15 min. 
Main compression force and pre-compression force may 
have impact on Hardness of tablets which will have 
impact on drug product CQA drug release. 
Drug release in 0.1N HCl at 120 min = 
+5.63+2.63*A+1.13*B 
(F=24.62, P˂0.0001, R2=0.908) 
Drug release in pH 6.5 SIF at 15 min = +68.13-4.13*A 
(F=11.54, P˂0.0001, R2=0.65) 
From equation it is observed that Main compression 
force and Pre-compression force have positive effect on 
drug release in 0.1N HCl. Increase in Main compression 
force leads to breakage of coating film around pellets 
which will have impact on drug release. Pareto chart 
(Fig.1e), also shows that main compression force t-limit 
is above Bonferroni limits showing certainly significant 
whereas pre-compression force showed limits above t-
limit showing possibly significant. 
In case of response Drug release in pH 6.5 SIF at 15 
min, only Main compression have significant impact 
(negative) same was observed in pareto chart (Fig.1f). 
Optimization using regression analysis and 
validation of mathematical model 
With the help of above mentioned mathematical models, 
process variables were optimized keeping the constraints 
in range to have design space. The optimum calculated 
parameters were  
X1: Main compression force: 11.33 kN 
X2: Pre-compression force: 2.72 kN 
X3: Turret speed: 23.56 rpm 
The experiments were carried out according to the 
process parameters obtained after applying constraints, 
and the optimum solution with process parameters was 
evaluated for its considered responses. Results obtained 
for responses are shown in table 6. In order to evaluate 
the reliability of the mathematical model developed, 
three additional checkpoints were taken, and estimated 
using a generated model covering the entire 
experimental domain. Table 6 gives the levels of 
variables of optimum formulation and three random 
checkpoints with their experimental values, predicted 
values, and the percent bias. 
For the optimum solution process parameters (Table 6), 
Y1 Experimental was 2.16 (Y1 predicted, 2.22; percent 
bias, 0.06%), Y2 Experimental was found to be 14.90 
(Y2 predicted, 15.68; percent bias,0.78),Y3 Experimental 
was found to be 6.97 (Y3 predicted, 6.99; percent 
bias,0.02), Y4 Experimental was found to be 3.81 (Y4 
predicted, 3.77; percent bias,-0.04), Y5 Experimental 
was found to be 5.0 (Y5 predicted, 5.74; percent 
bias,0.74) & Y6 Experimental was found to be 68.0% 
(Y6 predicted, 67.44; percent bias,-0.56) in the current 
study indicate the robustness of the mathematical model. 
Based on above optimization studies, updated risk 
assessment was performed reducing the risk of evaluated 
process parameters on drug product CQA’s from High to 
low and Medium to low shown in table 7. 
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Table 6: The experimental and predicted values for evaluated responses Y1– Y6 along with percentage prediction 
error observed for optimum run (1) and random runs (2, 3 and 4). 
Number Main 
compression 
force (kN) 
Pre-
compression 
force (kN) 
Turret 
speed 
(rpm) 
Response 
variables 
Predicted 
Values 
Experimental 
values 
#Bias 
(%) 
1 11.33 2.72 23.56 
Y1 2.22 2.16 0.06 
Y2 15.68 14.90 0.78 
Y3 6.99 6.97 0.02 
Y4 3.77 3.81 -0.04 
Y5 5.74 5.0 0.74 
Y6 67.44 68.0 -0.56 
2 13.00 2.00 15.00 
Y1 2.17 2.29 -0.12 
Y2 18.38 17.69 0.69 
Y3 6.86 6.83 0.03 
Y4 2.62 2.89 -0.27 
Y5 7.12 6.00 1.12 
Y6 64.00 66.0 -2 
3 9.38 3.48 22.97 
Y1 1.94 2.09 -0.15 
Y2 12.49 11.23 1.26 
Y3 7.14 7.03 0.11 
Y4 3.69 3.56 0.13 
Y5 4.05 3.0 1.05 
Y6 71.45 69.0 2.45 
4 12.61 2.51 22.97 
Y1 2.39 2.46 -0.07 
Y2 17.93 18.06 -0.13 
Y3 6.88 6.81 0.07 
Y4 3.69 3.24 0.45 
Y5 7.19 6.0 1.19 
Y6 64.79 64.0 0.79 
Note: #Bias (%) = (experimental value-predicted value)/experimental value × 100 
 
Table 7: Updated Risk Assessment for Compression Process Variables 
CQA's 
Compression Process steps 
Tooling 
design 
Feeder 
speed 
Pre-
compression 
force 
Main 
compression 
force 
Turret 
speed 
Ejection 
force 
Environmental 
conditions 
Intermediate CQA's 
Weight Variation Low Low Low Low High Low Low 
Hardness Low Low Low Low Low Low Low 
Thickness Low Low Low Low Low Low Low 
Finished product CQA's 
Assay  Low Low Low Low Low Low Low 
Dissolution Low Low Low Low Low Low Low 
Uniformity of 
Dosage Units by 
content 
uniformity 
Low Low Low Low Low Low Low 
Water content Low Low Low Low Low Low Low 
Related 
Substances 
Low Low Low Low Low Low Low 
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Figure 1: Graphical analysis by pareto chart for evaluation of effects on both the selected responses a) Y1, Weight Variation % RSDb) Y2, Hardness c) Y3, Thickness d) Y4, 
Content Uniformity – AV value e) Y5, Drug release in 0.1N HCl at 120 min.f) Y6 , Drug release in pH6.5 SIF, at 15min.  
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CONCLUSION 
Process optimization of Esomeprazole MUPS at 
compression stage was carried out using a three-factor, 
two-level, full factorial design. This allowed rapid 
evaluation and identification of the process parameters 
important in determining the desired responses. The 
impact of varying the levels of Main compression force, 
Pre-compression force and Turret speed on independent 
variables Viz. Weight variation - % RSD, Hardness, 
Thickness, Content uniformity and Drug release was 
investigated. ANOVA analysis showed all models for 
selected responses were significant. The mathematical 
model for each of the responses developed using 
multiple regression analysis quantitatively describes the 
influence of the selected variables on the responses 
under investigation. Regression analysis showed R
2
 
values more than 0.90 which indicates that the model 
explains all the variability of the response data around its 
mean. For optimized run observed responses were in 
close agreement with the predicted values, indicating 
excellent predictability of the optimization procedure.  
The formulation with optimized process variables 
showed weight Variation- RSD: 2.16 %, 
Hardness:14.90Kp, Thickness: 6.97mm, Content 
uniformity: AV value -3.81, Drug release in 0.1N HCl at 
120min: 5.0% and Drug release in pH 6.5 SIF at 15min: 
68% in the current study indicate the robustness of the 
mathematical model. From above studies, it is concluded 
that a quality Esomeprazole MUPS tablet was 
successfully evaluated designed using QbD approach for 
compression process variables. 
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